课题基金 / 基金详情

Production of chimeric monoclonal antibodies to Pim1, a novel therapeutic target for cancer treatment

Production of chimeric monoclonal antibodies to Pim1, a novel therapeutic target for cancer treatment
生产针对 Pim1 的嵌合单​​克隆抗体,这是一种癌症治疗的新型治疗靶点
批准号:
nhmrc : 434111
负责人:
A/Pr Pei Xing
金额:
$12.59万
依托单位国家:
澳大利亚
项目类别:
NHMRC Development Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2007-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
几乎六分之一的男性在一生中会患上前列腺癌。每年,大约有10,000名澳大利亚男性被诊断出患有前列腺癌,超过2,500人死于这种疾病,使前列腺癌成为仅次于肺癌的男性癌症死亡的第二大原因。过去10年来,前列腺癌的研究进展令人鼓舞。然而,五年生存率仍然很低。迫切需要开发治疗这种疾病的新方法。最近出现了一个令人兴奋的原则,使用单克隆抗体(Mab),如赫赛汀(一种人源化抗HER 2 Mab),目前已被广泛用于治疗乳腺癌。我们制备了2种针对Pim 1的单克隆抗体,其在小鼠前列腺癌模型中显著抑制前列腺癌细胞生长。Pim 1是一种新的癌蛋白,是治疗前列腺癌的生物标志物,因为它在超过90%的前列腺癌中过表达,但在正常前列腺中不表达或表达较少,通过基因阵列和免疫组织化学染色证实。Pim 1在细胞存活、增殖和转移中起重要作用。Pim 1是一个新的靶点,抗Pim 1单克隆抗体可能对人类肿瘤的治疗有价值。然而,鼠源单克隆抗体不能在人体内重复使用,因为人源单克隆抗体会产生抗鼠抗体应答,并且鼠源单克隆抗体会迅速从循环中去除,这将极大地限制单克隆抗体的治疗潜力。幸运的是,这个问题可以通过使用杂交嵌合抗体来克服。在本研究中,我们将使用嵌合技术来人源化抗Pim 1单克隆抗体,并在体外和小鼠模型中对其进行临床前研究。我们已经获得了专利保护,我们有足够的知识和技术,有信心生产小鼠-人嵌合单克隆抗体用于未来的临床试验。我们也是未来临床试验的最佳选择,因为我们有商业化的经验。
英文摘要
Almost one in six men will develop prostate cancer during his lifetime. Every year, around 10,000 Australian men are diagnosed and more than 2,500 die of the disease, making prostate cancer the second largest cause of male cancer deaths after lung cancer. The research progress made on prostate cancer over the past 10 years has been encouraging. However the five-year survival rate remains low. There is a vital need to develop new methods to treat this disease. An exciting principle has emerged recently with the use of monoclonal antibodies (Mabs) such as Herceptin (a humanised anti-HER2 Mab), which is now being widely used to treat breast cancer. We produced 2 Mabs to Pim1, which significantly inhibited prostate cancer cell growth in mouse prostate cancer model. Pim1 is a novel oncoprotein, a biomarker for the treatment of prostate cancer as it overexpresses in more than 90% of prostate cancer, but not or less expressed in normal prostate, demonstrated by genearrays and immunohistochemical staining. Pim1 plays an important role in cell survival, proliferation and metastasis. Pim1 is a novel target, and the anti-Pim1 Mabs may be of value for the cancer therapy in humans. However, the murine Mab can not be repeatedly used in human because human would produce anti-mouse antibody response, and the murine Mab would be rapidly removed from circulation, which will greatly limit the therapeutic potential of the Mabs. Fortunately, the problem can be overcome by the use of hybrid chimeric antibodies. In this study, we are going to use chimeric technology to humanise the anti-Pim1 Mab and test them in vitro and in mouse model for the preclinical studies. We have had patent to protect our finding, and we are confident to produce mouse-human chimeric Mab for the future clinical trial as we have proper knowledge, techniques. We are also optimic for the future clinical trial as we have the experiences on commercialisation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
用细菌传递RNA干扰经肠道黏膜免疫系统治疗艾滋病毒感染
  • 批准号:
    30972624
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2009
  • 负责人:
    向双林
  • 依托单位: